



The Initial Gut Microbiota and Response to Antibiotic Perturbation Influence *Clostridioides difficile* Clearance in Mice

 Sarah Tomkovich,^a  Joshua M. A. Stough,^a Lucas Bishop,^a  Patrick D. Schloss^a

^aDepartment of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA

ABSTRACT The gut microbiota has a key role in determining susceptibility to *Clostridioides difficile* infections (CDIs). However, much of the mechanistic work examining CDIs in mouse models uses animals obtained from a single source. We treated mice from 6 sources (2 University of Michigan colonies and 4 commercial vendors) with clindamycin, followed by a *C. difficile* challenge, and then measured *C. difficile* colonization levels throughout the infection. The microbiota were profiled via 16S rRNA gene sequencing to examine the variation across sources and alterations due to clindamycin treatment and *C. difficile* challenge. While all mice were colonized 1 day postinfection, variation emerged from days 3 to 7 postinfection with animals from some sources colonized with *C. difficile* for longer and at higher levels. We identified bacteria that varied in relative abundance across sources and throughout the experiment. Some bacteria were consistently impacted by clindamycin treatment in all sources of mice, including *Lachnospiraceae*, *Ruminococcaceae*, and *Enterobacteriaceae*. To identify bacteria that were most important to colonization regardless of the source, we created logistic regression models that successfully classified mice based on whether they cleared *C. difficile* by 7 days postinfection using community composition data at baseline, post-clindamycin treatment, and 1 day postinfection. With these models, we identified 4 bacterial taxa that were predictive of whether *C. difficile* cleared. They varied across sources (*Bacteroides*) or were altered by clindamycin (*Porphyromonadaceae*) or both (*Enterobacteriaceae* and *Enterococcus*). Allowing for microbiota variation across sources better emulates human interindividual variation and can help identify bacterial drivers of phenotypic variation in the context of CDIs.

IMPORTANCE *Clostridioides difficile* is a leading nosocomial infection. Although perturbation to the gut microbiota is an established risk, there is variation in who becomes asymptotically colonized, develops an infection, or has adverse infection outcomes. Mouse models of *C. difficile* infection (CDI) are widely used to answer a variety of *C. difficile* pathogenesis questions. However, the interindividual variation between mice from the same breeding facility is less than what is observed in humans. Therefore, we challenged mice from 6 different breeding colonies with *C. difficile*. We found that the starting microbial community structures and *C. difficile* persistence varied by the source of mice. Interestingly, a subset of the bacteria that varied across sources were associated with how long *C. difficile* was able to colonize. By increasing the interindividual diversity of the starting communities, we were able to better model human diversity. This provided a more nuanced perspective of *C. difficile* pathogenesis.

KEYWORDS 16S rRNA, *Clostridioides difficile*, *Clostridium difficile*, microbial ecology, microbiome, microbiota

Antibiotics are a common risk factor for *Clostridioides difficile* infections (CDIs) due to their effect on the intestinal microbiota, but there is variation in who goes on to develop severe or recurrent CDIs after exposure (1, 2). Additionally, asymptomatic colonization, where *C. difficile* is detectable but symptoms are absent, has been

Citation Tomkovich S, Stough JMA, Bishop L, Schloss PD. 2020. The initial gut microbiota and response to antibiotic perturbation influence *Clostridioides difficile* clearance in mice. *mSphere* 5:e00869-20. <https://doi.org/10.1128/mSphere.00869-20>.

Editor Robert A. Britton, Baylor College of Medicine

Copyright © 2020 Tomkovich et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Patrick D. Schloss, pschloss@umich.edu.

 The initial gut microbiota influences *Clostridioides difficile* clearance in mice obtained from different sources. These results suggest that human models of *C. difficile* clearance should attempt to model the variation between people. @PatSchloss

Received 27 August 2020

Accepted 7 October 2020

Published 21 October 2020

documented in infants and adults (3, 4). The intestinal microbiota has been implicated in asymptomatic colonization (5, 6), susceptibility to CDIs (7, 80), and adverse CDI outcomes (8–11). However, it is not clear how much interindividual microbiota variation contributes to the range of outcomes observed after *C. difficile* exposure relative to other risk factors.

Mouse models of CDIs have been a great tool for understanding *C. difficile* pathogenesis (12). The number of CDI mouse model studies has grown substantially since Chen et al. published their C57BL/6 model in 2008, which disrupted the gut microbiota with antibiotics to enable *C. difficile* colonization and symptoms such as diarrhea and weight loss (13). CDI mouse models have been used to examine translationally relevant questions regarding *C. difficile*, including the role of the microbiota and the efficacy of potential therapeutics for treating CDIs (14). However, variation in the microbiota between mice from the same breeding colony is much less than the interindividual variation observed between humans (15, 16). Studying CDIs in mice with a homogeneous microbiota is likely to overstate the importance of individual mechanisms. Using mice that have a more heterogeneous microbiota would allow researchers to identify and validate more generalizable mechanisms responsible for CDI.

In the past, our group has attempted to introduce more variation into the mouse microbiota by using a variety of antibiotic treatments (17–20). An alternative approach to maximize microbiota variation is to use mice from multiple sources (21, 22). The differences between the microbiota of mice from vendors have been well documented and shown to influence susceptibility to a variety of diseases (23, 24), including enteric infections (21, 22, 25–29). Different research groups have also observed different CDI outcomes despite using similar murine models (12, 17, 20, 30–32). Here, we examined how variation in the baseline microbiota and responses to clindamycin treatment in C57BL/6 mice from six different sources influenced susceptibility to *C. difficile* colonization and the time needed to clear the infection.

RESULTS

The variation in the microbiota is high between mice from different sources.

We obtained C57BL/6 mice from 6 different sources: two colonies from the University of Michigan that were split from each other in 2010 (the Young and Schloss lab colonies) and four commercial vendors: the Jackson Laboratory, Charles River Laboratories, Taconic Biosciences, and Envigo (which was formerly Harlan). These 4 vendors were chosen because they are commonly used for murine CDI studies (25, 33–39). Two experiments were conducted, approximately 3 months apart.

We sequenced the V4 region of the 16S rRNA gene from fecal samples collected from these mice after they acclimated to the University of Michigan animal housing environment. We first examined the alpha diversity across the 6 sources of mice. There was a significant difference in the richness (i.e., number of observed operational taxonomic units [OTUs]) but not Shannon diversity index across the sources of mice ($P_{\text{FDR}} = 0.03$ and $P_{\text{FDR}} = 0.052$, respectively; Fig. 1A and B and also Data Set S1, sheets 1 and 2, in the supplemental material). Next, we compared the community structures of mice (Fig. 1C). The source of mice and the interactions between the source and cage effects explained most of the observed variation between fecal communities (permutational multivariate analysis of variance [PERMANOVA] combined $R^2 = 0.90$, $P < 0.001$; Fig. 1C and Data Set S1, sheet 3). Mice that are cohoused tend to have similar gut microbiotas due to coprophagy (40). Since mice within the same source were housed together, it was not surprising that the cage effect also contributed to the observed community variation. There were some differences between the 2 experiments we conducted, as the experiment and cage effects significantly explained the observed community variation for the Schloss and Young lab mouse colonies (Fig. S1A and B and Data Set S1, sheet 4). However, most of the vendors also clustered by experiment (Fig. S1C, D, and F), suggesting there was some community variation between the 2 experiments within each source, particularly for Schloss, Young, and Envigo mice (Fig. S1G and H). After finding differences at the community level, we next identified the




FIG 1 Microbiota variation is high between mice from different sources. (A and B) Number of observed OTUs (A) and Shannon diversity index values (B) across sources of mice at baseline (day -1 of the experiment). Differences between sources were analyzed by Kruskal-Wallis test with Benjamini-Hochberg correction for testing each day of the experiment, and the adjusted P value was <0.05 for panel A (Data Set S1, sheet 1). None of the P values from pairwise Wilcoxon comparisons between sources were significant after Benjamini-Hochberg correction (Data Set S1, sheet 2). Gray lines represent the median values for each source of mice. (C) Principal-coordinate analysis (PCoA) of θ_{VC} distances of baseline stool samples. Source and the interaction between source and cage effects explained most of the variation (PERMANOVA combined $R^2 = 0.90$, $P < 0.001$; Data Set S1, sheet 3). For panels A to C, each symbol represents the value for a stool sample from an individual mouse, circles represent experiment 1 mice, and triangles represent experiment 2 mice. (D) The median (point) and interquartile range (colored lines) of the relative abundances for the 20 most significant OTUs out of the 268 OTUs that varied across sources at baseline by Kruskal-Wallis test with Benjamini-Hochberg correction (Data Set S1, sheet 5).

bacteria that varied between sources of mice. There were 268 OTUs with relative abundances that were significantly different between the sources at baseline (Fig. 1D and Data Set S1, sheet 5). Though we saw differences between experiments at the community level, there were no OTUs that were significantly different between experiments within Schloss, Young, and Envigo mice at baseline (all $P > 0.05$). By using mice from six sources, we were able to increase the variation in the starting communities to evaluate in a clindamycin-based CDI model.

Clindamycin treatment renders all mice susceptible to *C. difficile* 630 colonization, but clearance time varies across sources. Clindamycin is frequently implicated with human CDIs (41) and was part of the antibiotic treatment for the frequently cited 2008 CDI mouse model (13). We have previously demonstrated that mice are rendered susceptible to *C. difficile* but clear the pathogen within 9 days; thus, colonization is transient when mice are treated with clindamycin alone (20, 42). All mice were treated with 10 mg clindamycin/kg of body weight via intraperitoneal injection and 1 day later challenged with 10^3 *C. difficile* 630 spores (Fig. 2A). The day after infection, *C. difficile* was detectable in all mice at similar levels (median CFU range: 2.2×10^7 to 1.3×10^8 ; $P_{FDR} = 0.15$), indicating that clindamycin rendered all mice susceptible regardless of source (Fig. 2B). However, between 3 and 7 days postinfection, we observed variation in *C. difficile* levels across sources of mice (all $P_{FDR} \leq 0.019$; Fig. 2B and Data Set S1, sheet 6). This suggested the source of mice was associated with *C.*




FIG 2 Clindamycin is sufficient to promote *C. difficile* colonization in all mice, but clearance time varies across sources. (A) Setup of the experimental timeline. Mice for the experiments were obtained from 6 different sources: the Schloss ($n = 8$) and Young lab ($n = 9$) colonies at the University of Michigan, the Jackson Laboratory ($n = 8$), Charles River Laboratories ($n = 8$), Taconic Biosciences ($n = 8$), and Envigo ($n = 8$). Mice that were ordered from commercial vendors acclimated to the University of Michigan mouse facility for 13 days prior to antibiotic administration. All mice were administered 10-mg/kg clindamycin intraperitoneally (IP) 1 day before challenge with *C. difficile* 630 spores on day 0. Mice were weighed and feces were collected daily through the end of the experiment (9 days postinfection). Note that 3 mice died during the course of the experiment: 1 Taconic mouse prior to infection and 1 Jackson and 1 Envigo mouse between 1 and 3 days postinfection. (B) *C. difficile* CFU/gram stool measured over time ($n = 20$ to 49 mice per time point) via serial dilutions. The black line represents the limit of detection for the first serial dilution. CFU quantification data were not available for each mouse due to early deaths, stool sampling difficulties, and not plating all of the serial dilutions. (C) Mouse weight change measured in grams over time ($n = 45$ to 49 mice per time point); all mice were normalized to the weight recorded 1 day before infection. For panels B and C, time points where differences between sources of mice were statistically significant by Kruskal-Wallis test with Benjamini-Hochberg correction for testing across multiple days (Data Set S1, sheets 6 and 7) are reflected by the asterisk above each time point (*, $P < 0.05$). Lines represent the median for each source, and circles represent individual mice from experiment 1, while triangles represent mice from experiment 2.

difficile clearance. While the colonization dynamics were similar between the two experiments, the Schloss mice took longer to clear *C. difficile* in the first experiment than in the second and the Envigo mice took longer to clear *C. difficile* in the second experiment than in the first (Fig. S2A and B). The change in the mice's weight significantly varied across sources of mice with the most weight loss occurring 2 days postinfection (Fig. 2C and Data Set S1, sheet 7). There was also one Jackson and one




FIG 3 Clindamycin treatment alters bacteria in all sources, but a subset of bacterial differences across sources persists. (A and B) Number of observed OTUs (A) and Shannon diversity index values (B) across sources of mice after clindamycin treatment (day 0). Differences between sources were analyzed by Kruskal-Wallis test with Benjamini-Hochberg correction for testing each day of the experiment, and the adjusted P value was <0.05 (Data Set S1, sheet 1). Significant P values from the pairwise Wilcoxon comparisons between sources with Benjamini-Hochberg correction are displayed as the first initial of each group compared to the group that they are listed above (Data Set S1, sheet 2). (C) PCoA of θ_{VC} distances from stools collected post-clindamycin treatment. Source and the interaction between source and cage effects explained most of the variation observed post-clindamycin treatment (PERMANOVA combined $R^2 = 0.99$, $P < 0.001$; Data Set S1, sheet 3). For panels A to C, each symbol represents a stool sample from an individual mouse, with circles representing experiment 1 mice and triangles representing experiment 2 mice. (D) The median (point) and interquartile range (colored lines) of the relative abundances for the 18 OTUs (Data Set S1, sheet 8) that varied between sources after clindamycin treatment (day 0). (E) The median (point) and interquartile range (colored lines) of the top 10 most significant OTUs out of 153 with relative abundances that changed because of the clindamycin treatment (adjusted P value < 0.05). Data were analyzed by paired Wilcoxon signed-rank test of mice that had paired sequence data for baseline (day -1) and post-clindamycin-treatment (day 0) time points ($n = 31$), with Benjamini-Hochberg correction for testing all identified OTUs (Data Set S1, sheet 9). The gray vertical line indicates the limit of detection.

Envigo mouse that died between 1 and 3 days postinfection during the second experiment. Mice obtained from Jackson, Taconic, and Envigo tended to lose more weight, have higher *C. difficile* CFU levels, and take longer to clear the infection than the other sources of mice (although there was variation between experiments with Schloss and Envigo mice). This was particularly evident 7 days postinfection (Fig. 2B and C; Fig. S2C and D), when 57% of the mice were still colonized with *C. difficile* (Fig. S2E). By 9 days postinfection, the majority of the mice from all sources had cleared *C. difficile* with the exception of 1 Taconic mouse from the first experiment and 2 Envigo mice from the second experiment (Fig. 2B). Thus, clindamycin rendered all mice susceptible to *C. difficile* 630 colonization, regardless of source, but there was significant variation in disease phenotype across the sources of mice.

Clindamycin treatment alters bacteria in all sources, but a subset of bacterial differences across sources persists. Given the variation in fecal communities that we observed across breeding colonies, we hypothesized that variation in *C. difficile* clearance would be explained by community variation across the 6 sources of mice. As expected, clindamycin treatment decreased the richness and Shannon diversity across all sources of mice (Fig. 3A and B). Interestingly, significant differences in diversity

metrics between sources emerged after clindamycin treatment, with Charles River mice having higher richness and Shannon diversity than most of the other sources ($P_{\text{FDR}} < 0.05$; Fig. 3A and B and Data Set S1, sheets 1 and 2). The clindamycin treatment decreased the variation in community structures between sources of mice. The source of mice and the interactions between source and cage effects explained almost all of the observed variation between communities (combined $R^2 = 0.99$, $P < 0.001$; Fig. 3C and Data Set S1, sheet 3). However, there were only 18 OTUs with relative abundances that significantly varied between sources after clindamycin treatment (Fig. 3D and Data Set S1, sheet 8). Next, we identified the bacteria that shifted after clindamycin treatment, regardless of source, by analyzing paired fecal samples from mice that were collected at baseline and after clindamycin treatment. We identified 153 OTUs that were altered after clindamycin treatment in most mice (Fig. 3E and Data Set S1, sheet 9). When we compared the list of significantly clindamycin-impacted bacteria with the bacteria that varied between sources post-clindamycin treatment, we found 4 OTUs that were shared between the lists (*Enterobacteriaceae* [OTU 1], *Lachnospiraceae* [OTU 130], *Lactobacillus* [OTU 6], and *Enterococcus* [OTU 23]; Fig. 3D and E and Data Set S1, sheets 8 and 9). Importantly, some of the OTUs that varied between sources also shifted with clindamycin treatment. For example, *Proteus* increased after clindamycin treatment (Fig. 3D), but only in Taconic mice. *Enterococcus* was primarily found in mice purchased from commercial vendors and also increased in relative abundance after clindamycin treatment (Fig. 3D). These findings demonstrate that clindamycin had a consistent impact on the fecal bacterial communities of mice from all sources and only a subset of the OTUs continued to vary between sources.

Microbiota variation between sources is maintained after *C. difficile* challenge.

One day postinfection, significant differences in diversity metrics remained across sources ($P_{\text{FDR}} < 0.05$, Fig. 4A and B and Data Set S1, sheets 1 and 2). Although the Charles River mice had more diverse communities and were also able to clear *C. difficile* faster than the other sources, diversity did not explain the observed variation in *C. difficile* colonization across sources. The Young and Schloss mice had the lowest diversity 1 day postinfection and were able to clear *C. difficile* earlier than Jackson, Taconic, and Envigo mice. The source of mice and the interactions between source and cage effects continued to explain most of the observed community variation (combined $R^2 = 0.88$; $P < 0.001$; Fig. 4C and Data Set S1, sheet 3). One day after *C. difficile* challenge, there were 44 OTUs with significantly different relative abundances across sources (Fig. 4D and Data Set S1, sheet 10).

Throughout the experiment, the source of mice continued to be the dominant factor that explained the observed variation across fecal communities (PERMANOVA $R^2 = 0.35$, $P < 0.001$) followed by interactions between cage effects and the day of the experiment (Movie S1 and Data Set S1, sheet 11). Fecal samples from the same source of mice continued to cluster closely with each other throughout the experiment. By 7 days postinfection, when approximately 43% of mice had cleared *C. difficile*, most of the mice had not recovered to their baseline community structure (Fig. 4E). The distance to the baseline community did not explain the variation in *C. difficile* clearance as the Schloss and Young mice had mostly cleared *C. difficile*, but their communities were a greater distance from baseline 7 days postinfection compared to the Jackson and Taconic mice that were still colonized. In summary, mouse bacterial communities varied significantly between sources throughout the course of the experiment, and a consistent subset of bacteria remained different between sources regardless of clindamycin and *C. difficile* challenge.

Baseline, post-clindamycin-treatment, and postinfection community data can predict mice that will clear *C. difficile* by 7 days postinfection. After identifying taxa that varied between sources, changed after clindamycin treatment, or both, we determined which taxa were influencing the variation in *C. difficile* colonization at day 7 (Fig. 2B and Fig. S2C). We trained three L2-regularized logistic regression models with either input bacterial community data from the 6 sources of mice at the baseline (day = -1), post-clindamycin-treatment (day = 0), or postinfection (day = 1) time




FIG 4 Microbiota variation across sources is maintained after *C. difficile* challenge. (A and B) Number of observed OTUs (A) and Shannon diversity index values (B) across sources of mice 1 day postinfection. Data were analyzed by Kruskal-Wallis test with Benjamini-Hochberg correction for testing each day of the experiment, and the adjusted P value was <0.05 (Data Set S1, sheet 1). Significant P values from the pairwise Wilcoxon comparisons between sources with Benjamini-Hochberg correction are displayed as the first initial of each group compared to the group that they are listed above (Data Set S1, sheet 2). (C) PCoA of θ_{VC} distances of 1-day-postinfection stool samples. Source and the interaction between source and cage effects explained most of the variation between fecal communities (PERMANOVA combined $R^2 = 0.88$, $P < 0.001$; Data Set S1, sheet 3). For panels A to C, each symbol represents the value for a stool sample from an individual mouse, circles represent experiment 1 mice, and triangles represent experiment 2 mice. (D) The median (point) and interquartile range (colored lines) of the relative abundances for the top 20 most significant OTUs out of the 44 OTUs that varied between sources 1 day postinfection. The gray vertical line indicates the limit of detection. For each time point, OTUs with differential relative abundances across sources of mice were identified by Kruskal-Wallis test with Benjamini-Hochberg correction for testing all identified OTUs (Data Set S1, sheet 10). (E) θ_{VC} distances of fecal samples collected 7 days postinfection relative to the baseline (day -1) sample for each mouse. Each symbol represents an individual mouse. Gray lines represent the median for each source.

points of the experiment to predict *C. difficile* colonization status on day 7 (Fig. S3A and B). All models were better at predicting *C. difficile* colonization status on day 7 than random chance (all $P < 0.001$, Data Set S1, sheet 12). The model based on the post-clindamycin-treatment (area under the receiving operator characteristic curve [AUROC] = 0.78) community OTU data performed significantly better than the baseline (AUROC = 0.72) or the postinfection (AUROC = 0.67) models ($P_{FDR} < 0.001$ for pairwise comparisons; Fig. S3C and Data Set S1, sheet 13). Thus, we were able to use bacterial relative abundance data from the time of *C. difficile* challenge to differentiate mice that had cleared *C. difficile* before day 7 from the mice still colonized with *C. difficile* at that

time point. This result suggests that the bacterial community's response to clindamycin treatment had the greatest influence on subsequent *C. difficile* colonization dynamics.

To examine the bacteria that were driving each model's performance, we selected the 20 OTUs that had the highest absolute feature weights in each of the 3 models (Data Set S1, sheet 14). First, we looked at OTUs from the model with the best performance, which was based on the post-clindamycin-treatment (day 0) bacterial community data. Out of the 10 highest-ranked OTUs, 7 OTUs were associated with *C. difficile* colonization 7 days postinfection (*Bacteroides*, *Escherichia/Shigella*, 2 *Lachnospiraceae*, *Lactobacillus*, *Porphyromonadaceae*, and *Ruminococcaceae*), while 3 OTUs were associated with clearance (*Enterobacteriaceae*, *Lachnospiraceae*, and *Porphyromonadaceae* [Fig. 5A]). On day 0, the majority of these OTUs were impacted by clindamycin and had relative abundances that were close to the limit of detection (Fig. 5A). Next, we examined whether any of the top 20 ranked OTUs from the post-clindamycin-treatment (day 0) model were also important in the other 2 classification models based on baseline (day -1) and 1 day postinfection community data. We identified 6 OTUs that were important to the post-clindamycin-treatment model and either the baseline or 1-day-postinfection models (*Enterobacteriaceae*, *Ruminococcaceae*, *Lactobacillus*, *Bacteroides*, *Porphyromonadaceae*, and *Erysipelotrichaceae* [Data Set S1, sheet 14]). Thus, a subset of bacterial OTUs were important for determining *C. difficile* colonization dynamics across multiple time points.


To determine whether the OTUs driving the classification models also varied between sources, were altered by clindamycin treatment, or both, we identified the OTUs from each model that varied between sources (Fig. 1D, Fig. 3D, and Fig. 4D and Data Set S1, sheets 5, 8, and 10) or were impacted by clindamycin treatment (Fig. 3E; Data Set S1, sheet 9; and Fig. 54). Comparing the features important to the 3 models identified 14 OTUs associated with source, 21 OTUs associated with clindamycin treatment, and 6 OTUs associated with both (Fig. 5B). Together, these results suggest that the initial bacterial communities and their responses to clindamycin influenced the clearance of *C. difficile*.

Several OTUs that overlapped with our previous analyses appeared across at least 2 models (*Bacteroides*, *Enterococcus*, *Enterobacteriaceae*, and *Porphyromonadaceae*), so we examined how the relative abundances of these OTUs varied over the course of the experiment (Fig. 6). Across the 9 days postinfection, there was at least 1 time point when the relative abundances of these OTUs significantly varied between sources (Data Set S1, sheet 15). Interestingly, there were no OTUs that emerged as consistently enriched or depleted in mice that were colonized past 7 days postinfection, suggesting that multiple bacteria influence *C. difficile* colonization dynamics.

DISCUSSION

Applying our CDI model to 6 different sources of mice allowed us to identify bacterial taxa that were unique to different sources as well as taxa that were universally impacted by clindamycin. We trained L2-regularized logistic regression models with baseline (day -1), post-clindamycin-treatment (day 0), and 1-day-postinfection fecal community data that could predict whether mice cleared *C. difficile* by 7 days postinfection better than random chance. We identified *Bacteroides*, *Enterococcus*, *Enterobacteriaceae*, and *Porphyromonadaceae* (Fig. 6) as candidate bacteria within these communities that influenced variation in *C. difficile* colonization dynamics, since these bacteria were all important in the logistic regression models and varied by source, were impacted by clindamycin treatment, or both. Overall, our results demonstrated that clindamycin was sufficient to render mice from multiple sources susceptible to CDI, and only a subset of the interindividual microbiota variation across mice from different sources was needed to predict which mice could clear *C. difficile*.

Other studies have used mice from multiple sources to identify bacteria that either promote colonization resistance or increase susceptibility to enteric infections (21, 22, 25–29). For example, against *Salmonella* infections, *Enterobacteriaceae* and segmented filamentous bacteria have emerged as protective (21, 26). We found *Enterobacteriaceae*



B OTU comparisons for day -1, 0, and 1 models




FIG 5 Bacteria that influenced whether mice cleared *C. difficile* by day 7. (A) Post-clindamycin-treatment (day 0) relative abundance data for the 10 OTUs with the highest rankings based on feature weights in the post-clindamycin-treatment (day 0) classification model. Red font represents OTUs that correlated with *C. difficile* colonization, and blue font represents OTUs that correlated with clearance. Symbols represent the relative abundance data for an individual mouse. Gray bars indicate the median relative abundances for each source. The gray horizontal lines indicate the limit of detection. (B) Venn diagram that combines OTUs that were important to the day -1, 0, and 1 classification models (Fig. S4 and Data Set S1, sheet 14) and either overlapped taxa that varied across sources at the same time point, were impacted by clindamycin treatment, or both. Bold OTUs were important to more than 1 classification model.

increased in all sources of mice after clindamycin treatment, positively correlating with *C. difficile* colonization. However, there was also variation in *Enterobacteriaceae* relative abundance levels between sources that was associated with the variation in *C. difficile* colonization dynamics across sources. Thus, bacteria may have differential roles in determining susceptibility depending on the type of bacterial infection.




FIG 6 OTUs associated with *C. difficile* colonization dynamics vary across sources throughout the experiment. (A and D) Relative abundances of bold OTUs from Fig. 5B that were important in at least two classification models are shown over time. (A) *Bacteroides* (OTU 2), which varied across sources throughout the experiment. (B and C) *Enterobacteriaceae* (B) and *Enterococcus* (C), which significantly varied across sources and were impacted by clindamycin treatment. (D) *Porphyromonadaceae* (OTU 7), which was significantly impacted by clindamycin treatment and, after examining relative abundance dynamics over the course of the experiment, was found to also significantly vary between sources of mice on days -1, 5, 6, 7, and 9 of the experiment. Symbols represent the relative abundance data for an individual mouse. Colored lines indicate the median relative abundances for each source. The gray horizontal line represents the limit of detection. Time points where differences between sources of mice were statistically significant by Kruskal-Wallis test with Benjamini-Hochberg correction for testing across multiple days (Data Set S1, sheet 15) are identified by the asterisk above each time point (*, $P < 0.05$).

Differences in CDI mouse model studies have been attributed to intestinal microbiota variation across sources. For example, researchers using the same clindamycin treatment and C57BL/6 mice had different *C. difficile* outcomes, one having sustained colonization (31) while the other had transient colonization (17), despite both using *C. difficile* VPI 10643. Baseline differences in the microbiota composition have been hypothesized to partially explain the differences in colonization outcomes and overall susceptibility to *C. difficile* after treatment with the same antibiotic (12, 30). When we treated mice from 6 different sources with clindamycin and challenged them with *C. difficile* 630, we found that microbiota variation across sources impacted colonization outcomes but not susceptibility. A previous study with *C. difficile* identified an endogenous protective *C. difficile* strain, LEM1, that bloomed after antibiotic treatment in mice from Jackson or Charles River Laboratories, but not Taconic, and that protected mice against the more toxigenic *C. difficile* VPI 10463 (25). Given that we obtained mice from the same vendors, we checked all mice for endogenous *C. difficile* by plating stool samples that were collected after clindamycin treatment. However, we did not identify any endogenous *C. difficile* strains prior to challenge, suggesting there were no endogenous protective strains in the mice we received and that other bacteria mediated the variation in *C. difficile* colonization across sources. The *C. difficile* strain used could also be contributing to the variation in *C. difficile* outcomes seen across different research groups. For example, a group found differential colonization outcomes after clindamycin treatment, with *C. difficile* 630 and M68 infections eventually becoming undetectable while strain BI-7 remained detectable up to 70 days posttreatment (43). One study limitation is that we used only female mice. Sex has been shown to influence microbiota variation in mice (44), so we used female mice to reduce this confounding variable and also to match the sex used in previous CDI studies that administered clindamycin to mice (31, 32, 43, 45). The bacterial perturbations induced by clindamycin

treatment have been well characterized, and our findings agree with previous CDI mouse model work demonstrating that *Enterococcus* and *Enterobacteriaceae* were associated with *C. difficile* susceptibility and *Porphyromonadaceae*, *Lachnospiraceae*, *Ruminococcaceae*, and *Turicibacter* were associated with resistance (18, 20, 31, 32, 42, 43, 45, 46). While we have demonstrated that susceptibility is uniform across sources of mice after clindamycin treatment, there could be different outcomes for either susceptibility or clearance in the case of other antibiotic treatments.

We found the time needed to naturally clear *C. difficile* varied across sources of mice, implying that at least in the context of the same perturbation, microbiota differences influence infection outcome. More importantly, we were able to explain the variation observed across sources with a subset of OTUs that were also important for predicting *C. difficile* colonization status 7 days postinfection. Since all but 3 mice eventually cleared *C. difficile* 630 by 9 days postinfection and the model built with the post-clindamycin-treatment (day 0) OTU relative abundance data had the best performance, our results suggest clindamycin treatment had a larger role in determining *C. difficile* susceptibility and clearance than did the source of the mice.

Using mice from multiple sources successfully increased the interanimal variation. One alternative approach that has been used in some CDI studies is to associate mice with human microbiotas (47–52). However, a major caveat to this method is the substantial loss of human microbiota community members upon transfer to mice (53, 54). Additionally, with the exception of 2 recent studies (47, 48), most of these studies associated mice with just 1 type of human microbiota either from a single donor or from a single pool from multiple donors (49–52). This approach does not aid in the goal of modeling the interpersonal variation seen in humans to understand how the microbiota influences susceptibility to CDIs and adverse outcomes. Importantly, our study using mice from 6 different sources increased the variation between groups of mice compared to using 1 source alone, to better reflect the interindividual microbiota variation observed in humans.

Another motivation for associating mice with human microbiotas is to study the bacteria associated with the disease in humans. Decreased *Bifidobacterium*, *Porphyromonas*, *Ruminococcaceae*, and *Lachnospiraceae* and increased *Enterobacteriaceae*, *Enterococcus*, *Lactobacillus*, and *Proteus* numbers have all been associated with human CDIs (7). Encouragingly, these populations were well represented in our study, suggesting most of the mouse sources are suitable for gaining insights into the bacteria influencing *C. difficile* colonization and infections in humans. Important exceptions were *Enterococcus*, which was primarily absent from University of Michigan colonies, and *Proteus*, which was found only in Taconic mice. The fact that some CDI-associated bacteria were found only in a subset of mice has important implications for future CDI mouse model studies but also models the natural patchiness of microbial populations in humans.

Other microbiota and host factors that were outside the scope of our current study may also contribute to the differences in *C. difficile* colonization dynamics between sources of mice. The microbiota is composed of viruses, fungi, and parasites in addition to bacteria, and these nonbacterial members can also vary across sources of mice (55, 56). While our study focused solely on the bacterial portion, viruses and fungi have also begun to be implicated in the context of CDIs or fecal microbiota transplantation (FMT) treatments for recurrent CDIs (34, 57–60). Beyond community composition, the metabolic function of the microbiota also has a CDI signature (19, 46, 61, 62) and can vary across mice from different sources (63). For example, microbial metabolites, particularly secondary bile acids and butyrate production, have been implicated as important contributors to *C. difficile* resistance (32, 43). Interestingly, butyrate has previously been shown to vary across mouse vendors and mediated resistance to *Citrobacter rodentium* infection, a model of enterohemorrhagic and enteropathogenic *Escherichia coli* infections (22). Evidence for immunological toning differences in IgA and Th17 cells across mice from different vendors have also been documented (64, 65) and could influence the host response to CDI (66, 67), particularly relevant for *C. difficile* strains that induce more severe disease than *C. difficile* 630. The

outcome after *C. difficile* exposure depends on a multitude of factors, including genetics, age, diet, and immunity, all of which also influence the microbiota.

We have demonstrated that the ways in which baseline microbiotas from different mouse sources respond to clindamycin treatment influence the length of time that mice remained colonized with *C. difficile* 630. To better understand the contribution of the microbiota to *C. difficile* pathogenesis and treatments, using multiple sources of mice may yield more insights than a single source. Furthermore, for studies wanting to examine the interplay between particular bacteria such as *Enterococcus* and *C. difficile*, these results could serve as a resource for selecting mice to address the question. Using mice from multiple sources helps model the interpersonal microbiota variation among humans to aid our understanding of how the gut microbiota provides colonization resistance to CDIs.

MATERIALS AND METHODS

Animals. All experiments were approved by the University of Michigan Animal Care and Use Committee (IACUC) under protocol number PRO00006983. Female C57BL/6 mice were obtained from 6 different sources: The Jackson Laboratory, Charles River Laboratories, Taconic Biosciences, Envigo, and two colonies at the University of Michigan (the Schloss lab colony and the Young lab colony). The Young lab colony was originally established with mice purchased from Jackson in 2002, and the Schloss lab colony was established in 2010 with mice donated from the Young lab. The 4 groups of mice purchased from vendors were allowed to acclimate to the University of Michigan mouse facility for 13 days prior to starting the experiment. At least 4 female mice (age 5 to 10 weeks) were obtained per source, and mice from the same source were primarily housed at a density of 2 mice per cage. The experiment was repeated once, approximately 3 months after the start of the first experiment.

Antibiotic treatment. After the 13-day acclimation period, all mice received 10-mg/kg clindamycin (filter sterilized through a 0.22- μ m syringe filter prior to administration) via intraperitoneal injection (Fig. 1A).

***C. difficile* infection model.** Mice were challenged with 10^3 spores of *C. difficile* strain 630 via oral gavage postinfection 1 day after clindamycin treatment as described previously (20). Mouse weights and stool samples were taken daily through 9 days postinfection (Fig. 1A). Collected stool was split for *C. difficile* quantification and 16S rRNA sequencing analysis. For *C. difficile* quantification, stool samples were transferred to the anaerobic chamber, serially diluted in phosphate-buffered saline (PBS), plated on taurocholate-cycloserine-cefoxitin-fructose agar (TCCFA) plates, and counted after 24 h of incubation at 37°C under anaerobic conditions. A sample from the day 0 time point (post-clindamycin treatment and prior to *C. difficile* challenge) was also plated on TCCFA to ensure mice were not already colonized with *C. difficile* prior to infection. There were 3 deaths recorded over the course of the experiment: 1 Taconic mouse died prior to *C. difficile* challenge and 1 Jackson mouse and 1 Envigo mouse died between 1 and 3 days postinfection. Mice were categorized as cleared when no *C. difficile* was detected in the first serial dilution (limit of detection: 100 CFU). Stool samples for 16S rRNA sequencing were snap-frozen in liquid nitrogen and stored at -80°C until DNA extraction.

16S rRNA sequencing. DNA was extracted from -80°C -stored stool samples using the DNeasy PowerSoil HTP 96 kit (Qiagen) and an EpMotion 5075 automated pipetting system (Eppendorf). The V4 region was amplified for 16S rRNA with the AccuPrime Pfx DNA polymerase (Thermo Fisher Scientific) using custom barcoded primers, as previously described (68). The ZymoBIOMICS microbial community DNA standards were used as a mock community control (69), and water was used as a negative control per 96-well extraction plate. The PCR amplicons were cleaned up and normalized with the SequalPrep normalization plate kit (Thermo Fisher Scientific). Amplicons were pooled and quantified with the Kapa library quantification kit (Kapa Biosystems), prior to sequencing using the MiSeq system (Illumina).

16S rRNA gene sequence analysis. mothur (v. 1.43) was used to process all sequences (70) with a previously published protocol (68). Reads were combined and aligned with the SILVA reference database (71). Chimeras were removed with the VSEARCH algorithm, and taxonomic assignment was completed with a modified version (v16) of the Ribosomal Database Project reference database (v11.5) (72) with an 80% confidence cutoff. Operational taxonomic units (OTUs) were assigned with a 97% similarity threshold using the OptiClust algorithm (73). Based on the mock communities, our overall sequencing error rate was 0.0112% and all water controls had fewer than 1,000 sequences (range: 18 to 875). To account for uneven sequencing across samples, samples were rarefied to 5,437 sequences 1,000 times for alpha and beta diversity analyses and a single time to generate relative abundances for model training. Principal-coordinate analyses (PCoAs) were generated based on the Yue and Clayton measure of dissimilarity (θ_{YC}) distances (74). Permutational multivariate analysis of variance (PERMANOVA) was performed on mothur-generated θ_{YC} distance matrices with the adonis function in the vegan package (75) in R (76).

Classification model training and evaluation. Models were generated based on mice that were categorized as either cleared or colonized 7 days postinfection and had sequencing data from the baseline (day -1), post-clindamycin-treatment (day 0), and postinfection (day 1) time points of the experiment. Input bacterial community relative abundance data at the OTU level from the baseline, post-clindamycin-treatment, and 1-day-postinfection time points were used to generate 3 classification models that predicted *C. difficile* colonization status 7 days postinfection. The L2-regularized logistic regression models were trained and tested using the caret package (77) in R as previously described (78) with the exception that we used 60% training and 40% testing data splits for testing of the held-out test

data to measure model performance and repeated 2.5-fold cross-validation of the training data to select the best cost hyperparameter. The modified training-to-testing ratio was selected to accommodate the small number of samples in the data set. Code was modified from https://github.com/SchlossLab/ML_pipeline_microbiome to update the classification outcomes and change the data split ratios. The modified repository to regenerate our modeling analysis is available at https://github.com/tomkose/ML_pipeline_microbiome.

Statistical analysis. All statistical tests were performed in R (v 4.0.2) (76). The Kruskal-Wallis test was used to analyze differences in *C. difficile* CFU, mouse weight change, and alpha diversity across sources with a Benjamini-Hochberg correction for testing multiple time points, followed by pairwise Wilcoxon comparisons with Benjamini-Hochberg correction. For taxonomic analysis and generation of logistic regression model input data, *C. difficile* (OTU 20) was removed. Bacterial relative abundances that varied across sources at the OTU level were identified with the Kruskal-Wallis test with Benjamini-Hochberg correction for testing all identified OTUs, followed by pairwise Wilcoxon comparisons with Benjamini-Hochberg correction. The Wilcoxon rank sum test was used to test for OTUs that differed between experiments within the Schloss, Young, and Envigo sources with Benjamini-Hochberg correction for testing all identified OTUs. OTUs impacted by clindamycin treatment were identified using the paired Wilcoxon signed-rank test with matched pairs of mouse samples from day -1 and day 0. To determine whether classification models had better performance (test AUROCs) than random chance (0.5), we used the one-sample Wilcoxon signed-rank test. To examine whether there was an overall difference in predictive performance across the 3 classification models, we used the Kruskal-Wallis test followed by pairwise Wilcoxon comparisons with Benjamini-Hochberg correction for multiple hypothesis testing. The tidyverse package (v 1.3.0) was used to wrangle and graph data (79).

Code availability. Code for all data analysis and generating the manuscript is available at https://github.com/SchlossLab/Tomkovich_Vendor_mSphere_2020. The modified repository to regenerate our modeling analysis is available at https://github.com/tomkose/ML_pipeline_microbiome.

Data availability. The 16S rRNA sequencing data have been deposited in the National Center for Biotechnology Information Sequence Read Archive (BioProject accession no. [PRJNA608529](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA608529)).

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

FIG S1, TIF file, 0.4 MB.

FIG S2, TIF file, 0.7 MB.

FIG S3, TIF file, 0.3 MB.

FIG S4, TIF file, 0.9 MB.

DATA SET S1, XLSX file, 0.2 MB.

MOVIE S1, MOV file, 0.2 MB.

ACKNOWLEDGMENTS

This work was supported by the National Institutes of Health (U01AI124255). S.T. was supported by the Michigan Institute for Clinical and Health Research Postdoctoral Translation Scholars Program (UL1TR002240 from the National Center for Advancing Translational Sciences).

We thank members of the Schloss lab for feedback on planning the experiments and data presentation. In particular, we thank Begüm Topçuoğlu for help with implementing logistic regression models, Ana Taylor for help with medium preparation and sample collection, and Nicholas Lesniak for his critical feedback on the manuscript. We also thank members of Vincent Young's lab, particularly Kimberly Vendrov, for guidance with the *C. difficile* infection mouse model and donating the mice. We also thank the Unit for Laboratory Animal Medicine at the University of Michigan for maintaining our mouse colony and providing the institutional support for our mouse experiments. Finally, we thank Kwi Kim, Austin Campbell, and Kimberly Vendrov for their help in maintaining the Schloss lab's anaerobic chamber.

REFERENCES

1. Teng C, Reveles KR, Obodozie-Ofoegbu OO, Frei CR. 2019. *Clostridium difficile* infection risk with important antibiotic classes: an analysis of the FDA adverse event reporting system. *Int J Med Sci* 16:630–635. <https://doi.org/10.7150/ijms.30739>.
2. Kelly CP. 2012. Can we identify patients at high risk of recurrent *Clostridium difficile* infection? *Clin Microbiol Infect* 18:21–27. <https://doi.org/10.1111/1469-0691.12046>.
3. Zacharioudakis IM, Zervou FN, Pliakos EE, Ziakas PD, Mylonakis E. 2015. Colonization with toxinogenic *C. difficile* upon hospital admission, and risk of infection: a systematic review and meta-analysis. *Am J Gastroenterol* 110:381–390. <https://doi.org/10.1038/ajg.2015.22>.
4. Crobach MJT, Vernon JJ, Loo VG, Kong LY, Péchiné S, Wilcox MH, Kuijper EJ. 2018. Understanding *Clostridium difficile* colonization. *Clin Microbiol Rev* 31:e00021-17. <https://doi.org/10.1128/CMR.00021-17>.
5. Zhang L, Dong D, Jiang C, Li Z, Wang X, Peng Y. 2015. Insight into alteration of gut microbiota in *Clostridium difficile* infection and asymptomatic *C. difficile* colonization. *Anaerobe* 34:1–7. <https://doi.org/10.1016/j.anaerobe.2015.03.008>.

6. VanInsberghe D, Elsherbini JA, Varian B, Poutahidis T, Erdman S, Polz MF. 2020. Diarrhoeal events can trigger long-term *Clostridium difficile* colonization with recurrent blooms. *Nat Microbiol* 5:642–650. <https://doi.org/10.1038/s41564-020-0668-2>.
7. Mancabelli L, Milani C, Lugli GA, Turroni F, Cocconi D, van Sinderen D, Ventura M. 2017. Identification of universal gut microbial biomarkers of common human intestinal diseases by meta-analysis. *FEMS Microbiol Ecol* 93:fix153. <https://doi.org/10.1093/femsec/fix153>.
8. Seekatz AM, Rao K, Santhosh K, Young VB. 2016. Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent *Clostridium difficile* infection. *Genome Med* 8:47. <https://doi.org/10.1186/s13073-016-0298-8>.
9. Khanna S, Montassier E, Schmidt B, Patel R, Knights D, Pardi DS, Kashyap PC. 2016. Gut microbiome predictors of treatment response and recurrence in primary *Clostridium difficile* infection. *Aliment Pharmacol Ther* 44:715–727. <https://doi.org/10.1111/apt.13750>.
10. Pakpour S, Bhanvadia A, Zhu R, Amarnani A, Gibbons SM, Gurry T, Alm EJ, Martello LA. 2017. Identifying predictive features of *Clostridium difficile* infection recurrence before, during, and after primary antibiotic treatment. *Microbiome* 5:148. <https://doi.org/10.1186/s40168-017-0368-1>.
11. Lee AA, Rao K, Limsrivilai J, Gilliland M, Malamet B, Briggs E, Young VB, Higgins PDR. 2020. Temporal gut microbial changes predict recurrent *Clostridioides difficile* infection in patients with and without ulcerative colitis. *Inflamm Bowel Dis* <https://doi.org/10.1093/ibd/izz335>.
12. Hutton ML, Mackin KE, Chakravorty A, Lyras D. 2014. Small animal models for the study of *Clostridium difficile* disease pathogenesis. *FEMS Microbiol Lett* 352:140–149. <https://doi.org/10.1111/1574-6968.12367>.
13. Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP. 2008. A mouse model of *Clostridium difficile*-associated disease. *Gastroenterology* 135:1984–1992. <https://doi.org/10.1053/j.gastro.2008.09.002>.
14. Best EL, Freeman J, Wilcox MH. 2012. Models for the study of *Clostridium difficile* infection. *Gut Microbes* 3:145–167. <https://doi.org/10.4161/gmic.19526>.
15. Baxter NT, Wan JJ, Schubert AM, Jenior ML, Myers P, Schloss PD. 2015. Intra- and interindividual variations mask interspecies variation in the microbiota of sympatric *Peromyscus* populations. *Appl Environ Microbiol* 81:396–404. <https://doi.org/10.1128/AEM.02303-14>.
16. Nagpal R, Wang S, Woods LCS, Seshie O, Chung ST, Shively CA, Register TC, Craft S, McClain DA, Yadav H. 2018. Comparative microbiome signatures and short-chain fatty acids in mouse, rat, non-human primate, and human feces. *Front Microbiol* 9:2897. <https://doi.org/10.3389/fmicb.2018.02897>.
17. Reeves AE, Theriot CM, Bergin IL, Huffnagle GB, Schloss PD, Young VB. 2011. The interplay between microbiome dynamics and pathogen dynamics in a murine model of *Clostridium difficile* infection. *Gut Microbes* 2:145–158. <https://doi.org/10.4161/gmic.2.3.16333>.
18. Schubert AM, Sinani H, Schloss PD. 2015. Antibiotic-induced alterations of the murine gut microbiota and subsequent effects on colonization resistance against *Clostridium difficile*. *mBio* 6:e00974-15. <https://doi.org/10.1128/mBio.00974-15>.
19. Jenior ML, Leslie JL, Young VB, Schloss PD. 2017. *Clostridium difficile* colonizes alternative nutrient niches during infection across distinct murine gut microbiomes. *mSystems* 2:e00063-17. <https://doi.org/10.1128/mSystems.00063-17>.
20. Jenior ML, Leslie JL, Young VB, Schloss PD. 2018. *Clostridium difficile* alters the structure and metabolism of distinct cecal microbiomes during initial infection to promote sustained colonization. *mSphere* 3:e00261-18. <https://doi.org/10.1128/mSphere.00261-18>.
21. Velazquez EM, Nguyen H, Heasley KT, Saechao CH, Gil LM, Rogers AWL, Miller BM, Rolston MR, Lopez CA, Litvak Y, Liou MJ, Faber F, Bronner DN, Tiffany CR, Byndloss MX, Byndloss AJ, Bäumlner AJ. 2019. Endogenous Enterobacteriaceae underlie variation in susceptibility to *Salmonella* infection. *Nat Microbiol* 4:1057–1064. <https://doi.org/10.1038/s41564-019-0407-8>.
22. Osbelt L, Thiemann S, Smit N, Lesker TR, Schröter M, Gálvez EJC, Schmidt-Hohagen K, Pils MC, Mühlen S, Dersch P, Hiller K, Schlüter D, Neumann-Schaal M, Strowig T. 2020. Variations in microbiota composition of laboratory mice influence *Citrobacter rodentium* infection via variable short-chain fatty acid production. *PLoS Pathog* 16:e1008448. <https://doi.org/10.1371/journal.ppat.1008448>.
23. Stough JMA, Dearth SP, Denny JE, LeClerc GR, Schmidt NW, Campagna SR, Wilhelm SW. 2016. Functional characteristics of the gut microbiome in C57BL/6 mice differentially susceptible to *Plasmodium yoelii*. *Front Microbiol* 7:1520. <https://doi.org/10.3389/fmicb.2016.01520>.
24. Alegre M-L. 2019. Mouse microbiomes: overlooked culprits of experimental variability. *Genome Biol* 20:108. <https://doi.org/10.1186/s13059-019-1723-2>.
25. Etienne-Mesmin L, Chassaing B, Adekunle O, Mattei LM, Bushman FD, Gewirtz AT. 2018. Toxin-positive *Clostridium difficile* latently infect mouse colonies and protect against highly pathogenic *C. difficile*. *Gut* 67: 860–871. <https://doi.org/10.1136/gutjnl-2016-313510>.
26. Lai NY, Musser MA, Pinho-Ribeiro FA, Baral P, Jacobson A, Ma P, Potts DE, Chen Z, Paik D, Soualhi S, Yan Y, Misra A, Goldstein K, Lagomarsino VN, Nordstrom A, Sivanathan KN, Wallrapp A, Kuchroo VK, Nowarski R, Starnbach MN, Shi H, Surana NK, An D, Wu C, Huh JR, Rao M, Chiu IM. 2020. Gut-innervating nociceptor neurons regulate Peyer's patch microfold cells and SFB levels to mediate *Salmonella* host defense. *Cell* 180:33–49.e22. <https://doi.org/10.1016/j.cell.2019.11.014>.
27. Thiemann S, Smit N, Roy U, Lesker TR, Gálvez EJC, Helmecke J, Basic M, Bleich A, Goodman AL, Kalinke U, Flavell RA, Erhardt M, Strowig T. 2017. Enhancement of IFN γ production by distinct commensals ameliorates *Salmonella*-induced disease. *Cell Host Microbe* 21:682–694.e5. <https://doi.org/10.1016/j.chom.2017.05.005>.
28. Rolig AS, Cech C, Ahler E, Carter JE, Ottemann KM. 2013. The degree of *Helicobacter pylori*-triggered inflammation is manipulated by preinfection host microbiota. *Infect Immun* 81:1382–1389. <https://doi.org/10.1128/IAI.00044-13>.
29. Ge Z, Sheh A, Feng Y, Muthupalani S, Ge L, Wang C, Kurnick S, Mannion A, Whary MT, Fox JG. 2018. *Helicobacter pylori*-infected C57BL/6 mice with different gastrointestinal microbiota have contrasting gastric pathology, microbial and host immune responses. *Sci Rep* 8:8014. <https://doi.org/10.1038/s41598-018-25927-2>.
30. Lawley TD, Young VB. 2013. Murine models to study *Clostridium difficile* infection and transmission. *Anaerobe* 24:94–97. <https://doi.org/10.1016/j.anaerobe.2013.09.008>.
31. Buffie CG, Jarchum I, Equinda M, Lipuma L, Gouberne A, Viale A, Ubeda C, Xavier J, Pamer EG. 2012. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to *Clostridium difficile*-induced colitis. *Infect Immun* 80:62–73. <https://doi.org/10.1128/IAI.05496-11>.
32. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gouberne A, No D, Liu H, Kinnebrew M, Viale A, Littmann E, van den Brink M, Jenq RR, Taur Y, Sander C, Cross JR, Toussaint NC, Xavier JB, Pamer EG. 2015. Precision microbiome reconstitution restores bile acid mediated resistance to *Clostridium difficile*. *Nature* 517:205–208. <https://doi.org/10.1038/nature13828>.
33. Spinler JK, Brown A, Ross CL, Boonma P, Conner ME, Savidge TC. 2016. Administration of probiotic kefir to mice with *Clostridium difficile* infection exacerbates disease. *Anaerobe* 40:54–57. <https://doi.org/10.1016/j.anaerobe.2016.05.008>.
34. Markey L, Shaban L, Green ER, Lemon KP, Mecas J, Kumamoto CA. 2018. Pre-colonization with the commensal fungus *Candida albicans* reduces murine susceptibility to *Clostridium difficile* infection. *Gut Microbes* 9:497–509. <https://doi.org/10.1080/19490976.2018.1465158>.
35. McKee RW, Aleksanyan N, Garrett EM, Tamayo R. 2018. Type IV pili promote *Clostridium difficile* adherence and persistence in a mouse model of infection. *Infect Immun* 86:e00943-17. <https://doi.org/10.1128/IAI.00943-17>.
36. Yamaguchi T, Konishi H, Aoki K, Ishii Y, Chono K, Tateda K. 2020. The gut microbiome diversity of *Clostridioides difficile*-inoculated mice treated with vancomycin and fidaxomicin. *J Infect Chemother* 26:483–491. <https://doi.org/10.1016/j.jiac.2019.12.020>.
37. Stroke IL, Letourneau JJ, Miller TE, Xu Y, Pechik I, Savoly DR, Ma L, Sturzenbecker LJ, Sabalski J, Stein PD, Webb ML, Hilbert DW. 2018. Treatment of *Clostridium difficile* infection with a small-molecule inhibitor of toxin UDP-glucose hydrolysis activity. *Antimicrob Agents Chemother* 62:e00107-18. <https://doi.org/10.1128/AAC.00107-18>.
38. Quigley L, Coakley M, Alemayehu D, Rea MC, Casey PG, O'Sullivan O, Murphy E, Kiely B, Cotter PD, Hill C, Ross RP. 2019. *Lactobacillus gasseri* APC 678 reduces shedding of the pathogen *Clostridium difficile* in a murine model. *Front Microbiol* 10:273. <https://doi.org/10.3389/fmicb.2019.00273>.
39. Mullish BH, McDonald JAK, Pechlivanis A, Allegretti JR, Kao D, Barker GF, Kapila D, Petrof EO, Joyce SA, Gahan CGM, Glegola-Madejska I, Williams HRT, Holmes E, Clarke TB, Thurst MR, Marchesi JR. 2019. Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent *Clostridioides difficile* infection. *Gut* 68: 1791–1800. <https://doi.org/10.1136/gutjnl-2018-317842>.

40. Nguyen TLA, Vieira-Silva S, Liston A, Raes J. 2015. How informative is the mouse for human gut microbiota research? *Dis Model Mech* 8:1–16. <https://doi.org/10.1242/dmm.017400>.
41. Guh AY, Kutty PK. 2018. *Clostridioides difficile* infection. *Ann Intern Med* 169:ITC49–ITC64. <https://doi.org/10.7326/AITC201810020>.
42. Tomkovich S, Lesniak NA, Li Y, Bishop L, Fitzgerald MJ, Schloss PD. 2019. The proton pump inhibitor omeprazole does not promote *Clostridioides difficile* colonization in a murine model. *mSphere* 4:e00693-19. <https://doi.org/10.1128/mSphere.00693-19>.
43. Lawley TD, Clare S, Walker AW, Stares MD, Connor TR, Raisen C, Goulding D, Rad R, Schreiber F, Brandt C, Deakin LJ, Pickard DJ, Duncan SH, Flint HJ, Clark TG, Parkhill J, Dougan G. 2012. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing *Clostridium difficile* disease in mice. *PLoS Pathog* 8:e1002995. <https://doi.org/10.1371/journal.ppat.1002995>.
44. Wang J, Lang T, Shen J, Dai J, Tian L, Wang X. 2019. Core gut bacteria analysis of healthy mice. *Front Microbiol* 10:887. <https://doi.org/10.3389/fmicb.2019.00887>.
45. Lawley TD, Clare S, Walker AW, Goulding D, Stabler RA, Croucher N, Mastroeni P, Scott P, Raisen C, Mottram L, Fairweather NF, Wren BW, Parkhill J, Dougan G. 2009. Antibiotic treatment of *Clostridium difficile* carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. *Infect Immun* 77:3661–3669. <https://doi.org/10.1128/IAI.00558-09>.
46. Jump RLP, Polinkovsky A, Hurless K, Sitzlar B, Eckart K, Tomas M, Deshpande A, Nerandzic MM, Donskey CJ. 2014. Metabolomics analysis identifies intestinal microbiota-derived biomarkers of colonization resistance in clindamycin-treated mice. *PLoS One* 9:e101267. <https://doi.org/10.1371/journal.pone.0101267>.
47. Nagao-Kitamoto H, Leslie JL, Kitamoto S, Jin C, Thomsson KA, Gilliland MG, Kuffa P, Goto Y, Jenq RR, Ishii C, Hirayama A, Seekatz AM, Martens EC, Eaton KA, Kao JY, Fukuda S, Higgins PDR, Kyrillos NG, Young VB, Kamada N. 2020. Interleukin-22-mediated host glycosylation prevents *Clostridioides difficile* infection by modulating the metabolic activity of the gut microbiota. *Nat Med* 26:608–617. <https://doi.org/10.1038/s41591-020-0764-0>.
48. Battaglioli EJ, Hale VL, Chen J, Jeraldo P, Ruiz-Mojica C, Schmidt BA, Rekdal VM, Till LM, Huq L, Smits SA, Moor WJ, Jones-Hall Y, Smyrk T, Khanna S, Pardi DS, Grover M, Patel R, Chia N, Nelson H, Sonnenburg JL, Farrugia G, Kashyap PC. 2018. *Clostridioides difficile* uses amino acids associated with gut microbial dysbiosis in a subset of patients with diarrhea. *Sci Transl Med* 10:eaam7019. <https://doi.org/10.1126/scitranslmed.aam7019>.
49. Robinson CD, Auchtung JM, Collins J, Britton RA. 2014. Epidemic *Clostridium difficile* strains demonstrate increased competitive fitness compared to nonepidemic isolates. *Infect Immun* 82:2815–2825. <https://doi.org/10.1128/IAI.01524-14>.
50. Collins J, Auchtung JM, Schaefer L, Eaton KA, Britton RA. 2015. Humanized microbiota mice as a model of recurrent *Clostridium difficile* disease. *Microbiome* 3:35. <https://doi.org/10.1186/s40168-015-0097-2>.
51. Collins J, Robinson C, Danhof H, Knetsch CW, van Leeuwen HC, Lawley TD, Auchtung JM, Britton RA. 2018. Dietary trehalose enhances virulence of epidemic *Clostridium difficile*. *Nature* 553:291–294. <https://doi.org/10.1038/nature25178>.
52. Hryckowian AJ, Treuren WV, Smits SA, Davis NM, Gardner JO, Bouley DM, Sonnenburg JL. 2018. Microbiota-accessible carbohydrates suppress *Clostridium difficile* infection in a murine model. *Nat Microbiol* 3:662–669. <https://doi.org/10.1038/s41564-018-0150-6>.
53. Fouladi F, Glenn EM, Bulik-Sullivan EC, Tsilimigras MCB, Sioda M, Thomas SA, Wang Y, Djukic Z, Tang Q, Tarantino LM, Bulik CM, Fodor AA, Carroll IM. 2020. Sequence variant analysis reveals poor correlations in microbial taxonomic abundance between humans and mice after gnotobiotic transfer. *ISME J* 14:1809–1820. <https://doi.org/10.1038/s41396-020-0645-z>.
54. Walter J, Armet AM, Finlay BB, Shanahan F. 2020. Establishing or exaggerating causality for the gut microbiome: lessons from human microbiota-associated rodents. *Cell* 180:221–232. <https://doi.org/10.1016/j.cell.2019.12.025>.
55. Rasmussen TS, de Vries L, Kot W, Hansen LH, Castro-Mejía JL, Vogensen FK, Hansen AK, Nielsen DS. 2019. Mouse vendor influence on the bacterial and viral gut composition exceeds the effect of diet. *Viruses* 11:435. <https://doi.org/10.3390/v11050435>.
56. Mims TS, Abdallah QA, Watts S, White C, Han J, Willis KA, Pierre JF. 2020. Variability in interkingdom gut microbiomes between different commercial vendors shapes fat gain in response to diet. *FASEB J* 34(S1):1. <https://doi.org/10.1096/fasebj.2020.34.s1.09906>.
57. Stewart DB, Wright JR, Fowler M, McLimans CJ, Tokarev V, Amaniera I, Baker O, Wong H-T, Brabec J, Drucker R, Lamendella R. 2019. Integrated meta-omics reveals a fungus-associated bacteriome and distinct functional pathways in *Clostridioides difficile* infection. *mSphere* 4:e00454-19. <https://doi.org/10.1128/mSphere.00454-19>.
58. Ott SJ, Waetzig GH, Rehman A, Moltzau-Anderson J, Bharti R, Grasis JA, Cassidy L, Tholey A, Fickenscher H, Seeger D, Rosenstiel P, Schreiber S. 2017. Efficacy of sterile fecal filtrate transfer for treating patients with *Clostridium difficile* infection. *Gastroenterology* 152:799–811.e7. <https://doi.org/10.1053/j.gastro.2016.11.010>.
59. Zuo T, Wong SH, Lam K, Lui R, Cheung K, Tang W, Ching JYL, Chan PKS, Chan MCW, Wu JCY, Chan FKL, Yu J, Sung JY, Ng SC. 2017. Bacteriophage transfer during faecal microbiota transplantation in *Clostridium difficile* infection is associated with treatment outcome. *Gut* 67:634–643. <https://doi.org/10.1136/gutjnl-2017-313952>.
60. Zuo T, Wong SH, Cheung CP, Lam K, Lui R, Cheung K, Zhang F, Tang W, Ching JYL, Wu JCY, Chan PKS, Sung JY, Yu J, Chan FKL, Ng SC. 2018. Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in *Clostridium difficile* infection. *Nat Commun* 9:3663. <https://doi.org/10.1038/s41467-018-06103-6>.
61. Robinson JI, Weir WH, Crowley JR, Hink T, Reske KA, Kwon JH, Burnham C-AD, Dubberke ER, Mucha PJ, Henderson JP. 2019. Metabolic networks connect host-microbiome processes to human *Clostridioides difficile* infections. *J Clin Invest* 129:3792–3806. <https://doi.org/10.1172/JCI126905>.
62. Fletcher JR, Erwin S, Lanzas C, Theriot CM. 2018. Shifts in the gut metabolome and *Clostridium difficile* transcriptome throughout colonization and infection in a mouse model. *mSphere* 3:e00089-18. <https://doi.org/10.1128/mSphere.00089-18>.
63. Xiao L, Feng Q, Liang S, Sonne SB, Xia Z, Qiu X, Li X, Long H, Zhang J, Zhang D, Liu C, Fang Z, Chou J, Glanville J, Hao Q, Kotowska D, Colding C, Licht TR, Wu D, Yu J, Sung JY, Liang Q, Li J, Jia H, Lan Z, Tremaroli V, Dworkynski P, Nielsen HB, Bäckhed F, Doré J, Chatelier EL, Ehrlich SD, Lin JC, Arumugam M, Wang J, Madsen L, Kristiansen K. 2015. A catalog of the mouse gut metagenome. *Nat Biotechnol* 33:1103–1108. <https://doi.org/10.1038/nbt.3353>.
64. Fransen F, Zagato E, Mazzini E, Fosso B, Manzari C, El Aidy S, Chiavelli A, D'Erchia AM, Sethi MK, Pabst O, Marzano M, Moretti S, Romani L, Penna G, Pesole G, Rescigno M. 2015. BALB/c and C57BL/6 mice differ in polyreactive IgA abundance, which impacts the generation of antigen-specific IgA and microbiota diversity. *Immunity* 43:527–540. <https://doi.org/10.1016/j.immuni.2015.08.011>.
65. Ivanov I, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb KC, Santee CA, Lynch SV, Tanoue T, Imaoka A, Itoh K, Takeda K, Umesaki Y, Honda K, Littman DR. 2009. Induction of intestinal th17 cells by segmented filamentous bacteria. *Cell* 139:485–498. <https://doi.org/10.1016/j.cell.2009.09.033>.
66. Azrad M, Hamo Z, Tkhawkho L, Peretz A. 2018. Elevated serum immunoglobulin A levels in patients with *Clostridium difficile* infection are associated with mortality. *Pathog Dis* 76:ft066. <https://doi.org/10.1093/femspd/ft066>.
67. Saleh MM, Frisbee AL, Leslie JL, Buonomo EL, Cowardin CA, Ma JZ, Simpson ME, Scully KW, Abhyankar MM, Petri WA. 2019. Colitis-induced th17 cells increase the risk for severe subsequent *Clostridium difficile* infection. *Cell Host Microbe* 25:756–765.e5. <https://doi.org/10.1016/j.chom.2019.03.003>.
68. Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. 2013. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. *Appl Environ Microbiol* 79:5112–5120. <https://doi.org/10.1128/AEM.01043-13>.
69. Sze MA, Schloss PD. 2019. The impact of DNA polymerase and number of rounds of amplification in PCR on 16S rRNA gene sequence data. *mSphere* 4:e00163-19. <https://doi.org/10.1128/mSphere.00163-19>.
70. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, Lesniewski RA, Oakley BB, Parks DH, Robinson CJ, Sahl JW, Stres B, Thallinger GG, Horn DJV, Weber CF. 2009. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. *Appl Environ Microbiol* 75:7537–7541. <https://doi.org/10.1128/AEM.01541-09>.
71. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J, Glöckner FO. 2013. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. *Nucleic Acids Res* 41:D590–D596. <https://doi.org/10.1093/nar/gks1219>.

72. Cole JR, Wang Q, Fish JA, Chai B, McGarrell DM, Sun Y, Brown CT, Porras-Alfaro A, Kuske CR, Tiedje JM. 2014. Ribosomal database project: data and tools for high throughput rRNA analysis. *Nucleic Acids Res* 42:D633–D642. <https://doi.org/10.1093/nar/gkt1244>.
73. Westcott SL, Schloss PD. 2017. OptiClust, an improved method for assigning amplicon-based sequence data to operational taxonomic units. *mSphere* 2:e00073-17. <https://doi.org/10.1128/mSphereDirect.00073-17>.
74. Yue JC, Clayton MK. 2005. A similarity measure based on species proportions. *Commun Stat Theory Methods* 34:2123–2131. <https://doi.org/10.1080/STA-200066418>.
75. Oksanen J, Blanchet FG, Friendly M, Kindt R, Legendre P, McGlenn D, Minchin PR, O'Hara RB, Simpson GL, Solymos P, Stevens MHH, Szoecs E, Wagner H. 2018. *Vegan: community ecology package*.
76. R Core Team. 2018. *R: a language and environment for statistical computing*. R Foundation for Statistical Computing, Vienna, Austria.
77. Kuhn M. 2008. Building predictive models in R using the caret package. *J Stat Softw* 28:1–26. <https://doi.org/10.18637/jss.v028.i05>.
78. Topçuoğlu BD, Lesniak NA, Ruffin MT, Wiens J, Schloss PD. 2020. A framework for effective application of machine learning to microbiome-based classification problems. *mBio* 11:e00434-20. <https://doi.org/10.1128/mBio.00434-20>.
79. Wickham H, Averick M, Bryan J, Chang W, McGowan LD, François R, Grolemund G, Hayes A, Henry L, Hester J, Kuhn M, Pedersen TL, Miller E, Bache SM, Müller K, Ooms J, Robinson D, Seidel DP, Spinu V, Takahashi K, Vaughan D, Wilke C, Woo K, Yutani H. 2019. Welcome to the tidyverse. *J Open Source Softw* 4:1686. <https://doi.org/10.21105/joss.01686>.
80. Duvallet C, Gibbons SM, Gurry T, Irizarry RA, Alm EJ. 2017. Meta-analysis of gut microbiome studies identifies disease-specific and shared responses. *Nat Commun* 8:1784. <https://doi.org/10.1038/s41467-017-01973-8>.